Pharmaceuticals News and Research

RSS

Cortex first-quarter net income increases to $0.08 per share

Cortex Pharmaceuticals, Inc. reported net income of approximately $5,596,000, or $0.08 per share for the quarter ended March 31, 2010 compared with a net loss of $3,168,000, or $0.07 per share for the corresponding prior year period, with the difference reflecting revenues from the Company's March 2010 transaction with Biovail Laboratories International SRL (Biovail).

17 May 2010

Inovio Biomedical changes corporate name to Inovio Pharmaceuticals

Inovio Biomedical Corporation, a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio's trading symbol remains the same.

17 May 2010

Soligenix first-quarter revenues decrease to $336,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010.

17 May 2010

Biostar Pharmaceuticals first-quarter 2010 revenues increase 66.0% to $12.4 million

Biostar Pharmaceuticals, Inc., a Xianyang- based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced financial results of the first quarter ended March 31, 2010.

17 May 2010

Jiangbo Pharmaceuticals third-quarter revenue decreases 0.6% to $25.6 million

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for the third quarter fiscal year 2010 ended March 31, 2010.

17 May 2010

Titan Pharmaceuticals reports total revenues of $2.4M for first-quarter 2010

Titan Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

17 May 2010

China Biologic first-quarter revenues up 28.1% to $27.1 million

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., today reported financial results for its first quarter ended March 31, 2010.

17 May 2010

Astellas Pharma, OSI Pharmaceuticals sign definitive merger agreement

Astellas Pharma Inc., a global pharmaceutical company, and OSI Pharmaceuticals, Inc., a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI.

17 May 2010

3SBio's first-quarter 2010 total net revenues up 40.5%

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2010.

17 May 2010

Enterprise Innovation Forum awards China Sky One Medical's CEO "Leadership Excellence in Innovation"

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China, today announced that Mr. Yan-Qing Liu, the Company's Chairman and Chief Executive Officer, received the award for "Leadership Excellence in Innovation" from the organizing committee of China Enterprise Innovation Forum.

15 May 2010

CEDF small business loan guarantee program to stem improper disposal of needles, prescription drugs

Connecticut waterways may be safer from biomedical waste, thanks to an innovative Community Economic Development Fund small business loan guarantee program. CEDF, with loan-program partners, Connecticut's Department of Economic and Community and the City of West Haven have guaranteed a small business loan to a West Haven company that stems improper disposal of needles and prescription drugs.

15 May 2010

NASDAQ Biotechnology Index semi-annual re-ranking to become effective May 24, 2010

The NASDAQ OMX Group, Inc. announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index®, which will become effective prior to market open on Monday, May 24, 2010.

15 May 2010

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

Saint John's Health Center Trustee and philanthropist Patrick Soon-Shiong, M.D., who developed the first FDA-approved protein nanoparticle treatment for cancer, has received the 2010 Distinguished Medical Science Award from the Friends of the National Library of Medicine for his significant contributions to the research and treatment of diabetes and cancer.

15 May 2010

Tips for cutting back on added sugar

Coca-Cola, Pepsi, Gatorade, and other drinks now come in versions made with "real" sugar as opposed to the often vilified high-fructose corn syrup. A whole swath of sugar alternatives are now available to consumers including the new BioVittoria, an extract of the monk fruit, which is grown in Southern China. But a new special report from Consumer Reports on Health questions whether turning to alternatives is the solution to America's growing obesity epidemic.

15 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Amended class action complaint against Pfizer

Robbins Geller Rudman & Dowd LLP ("Robbins Geller") today announced that an amended class action complaint will be filed in the United States District Court for the Southern District of New York. The amended complaint will be on behalf of purchasers of Pfizer Inc. publicly traded securities during the period between January 19, 2006 and January 23, 2009.

15 May 2010

Novartis employees organise events to contribute to community organizations

In a spring tradition that has become well entrenched at the company over the past 14 years, employees of Novartis from across Canada are today joining their colleagues around the world in taking time away from their work to contribute to community organizations.

15 May 2010

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

Protox Therapeutics Inc. a leader in the development of receptor targeted fusion proteins, today released financial results for the first quarter 2010, ended March 31, 2010. "The first quarter of 2010 marked significant achievements for the company, namely the announcement of positive top-line results from the TRIUMPH study and the subsequent completion of a five million dollar financing," said Dr. Fahar Merchant, President and CEO of Protox.

15 May 2010

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the parties have stipulated to a dismissal of the litigation.

15 May 2010

US Oncology Specialty passes VAWD accreditation program

US Oncology, Inc.'s Fort Worth, Texas distribution facility, US Oncology Specialty, LP, has once again successfully passed the National Association of Boards of Pharmacy Verified-Accredited Wholesale Distributors program's comprehensive criteria review and on-site inspection.

15 May 2010